Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?

Journal of Orthopaedic Research

Volumn 34, Issue 1, 2016, Pages 12-14

  Wei, Jian Lu ^a   Buza, John ^a   Liu, Chuan Ju ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INFLIXIMAB; INTERLEUKIN 1; PROGRANULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTHRITIS; CARTILAGE DEGENERATION; DISEASE SEVERITY; FRACTURE HEALING; HUMAN; LETTER; POST TRAUMATIC ARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS; ANIMAL; COMPLICATION; INTRAARTICULAR FRACTURE; JOINT; MALE; METABOLISM; OSTEOARTHRITIS; PATHOPHYSIOLOGY; SYNOVIUM;

ANIMALS; ARTHRITIS; INTRA-ARTICULAR FRACTURES; JOINTS; MALE; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84954077159     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.23091     Document Type: Letter

References (35)

1. Olson SA, Furman BD, Kraus VB, et al., 2015. Therapeutic opportunities to prevent post-traumatic arthritis: lessons from the natural history of arthritis after articular fracture. J Orthop Res 33: 1266-1277.
2. Furman BD, Strand J, Hembree WC, et al., 2007. Joint degeneration following closed intraarticular fracture in the mouse knee: a model of posttraumatic arthritis. J Orthop Res 25: 578-592.
3. Lewis JS, Hembree WC, Furman BD, et al., 2011. Acute joint pathology and synovial inflammation is associated with increased intra-articular fracture severity in the mouse knee. Osteoarthritis Cartilage 19: 864-873.
4. Lewis JS, Jr., Furman BD, Zeitler E, et al., 2013. Genetic and cellular evidence of decreased inflammation associated with reduced incidence of posttraumatic arthritis in MRL/MpJ mice. Arthritis Rheum 65: 660-670.
5. Furman BD, Mangiapani DS, Zeitler E, et al., 2014. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther 16: R134.
6. Kimmerling KA, Furman BD, Mangiapani DS, et al., 2015. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. Eur Cell Mater 29: 124-39; discussion 39-40.
7. Fazzalari NL,. 2011. Bone fracture and bone fracture repair. Osteoporos Int 22: 2003-2006.
8. Fukui N, Purple CR, Sandell LJ,. 2001. Cell biology of osteoarthritis: the chondrocyte's response to injury. Curr Rheumatol Rep 3: 496-505.
9. Aggarwal BB,. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745-756.
10. Hehlgans T, Pfeffer K,. 2005. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115: 1-20.
11. Aggarwal BB, Gupta SC, Kim JH,. 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119: 651-665.
12. Bluml S, Scheinecker C, Smolen JS, et al., 2012. Targeting TNF receptors in rheumatoid arthritis. Int Immunol 24: 275-281.
13. Peschon JJ, Torrance DS, Stocking KL, et al., 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-952.
14. McCann FE, Perocheau DP, Ruspi G, et al., 2014. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol 66: 2728-2738.
15. Higuchi Y, McTiernan CF, Frye CB, et al., 2004. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 109: 1892-1897.
16. Tang W, Lu Y, Tian QY, et al., 2011. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332: 478-484.
17. Zhao YP, Liu B, Tian QY, et al., 2014. Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signalling. Ann Rheum Dis.
18. Zhao YP, Tian QY, Frenkel S, et al., 2013. The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. Biomaterials 34: 6412-6421.
19. Zanocco-Marani T, Bateman A, Romano G, et al., 1999. Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res 59: 5331-5340.
20. Shoyab M, McDonald VL, Byles C, et al., 1990. Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. Proc Natl Acad Sci USA 87: 7912-7916.
21. Plowman GD, Green JM, Neubauer MG, et al., 1992. The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. J Biol Chem 267: 13073-13078.
22. Anakwe OO, Gerton GL,. 1990. Acrosome biogenesis begins during meiosis: evidence from the synthesis and distribution of an acrosomal glycoprotein, acrogranin, during guinea pig spermatogenesis. Biol Reprod 42: 317-328.
23. Zhou J, Gao G, Crabb JW, et al., 1993. Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line. J Biol Chem 268: 10863-10869.
24. Jian J, Zhao S, Tian Q, et al., 2013. Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. FEBS Lett 587: 3428-3436.
25. Wei FH, Zhang YY, Jian JL, et al., 2014. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. Sci Rep-Uk 4: 1-11.
26. Xia Q, Zhu S, Wu Y, et al., 2015. Intra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development. Stem Cells Transl Med 4: 523-531.
27. Bluml S, Binder NB, Niederreiter B, et al., 2010. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 62: 1608-1619.
28. Faustman D, Davis M,. 2010. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9: 482-493.
29. Aggarwal BB,. 2014. Editorial: balancing tumor necrosis factor receptor I and tumor necrosis factor receptor II jointly for joint inflammation. Arthritis Rheumatol 66: 2657-2660.
30. Ma CH, Lv Q, Yu YX, et al., 2015. Protective effects of tumor necrosis factor-alpha blockade by adalimumab on articular cartilage and subchondral bone in a rat model of osteoarthritis. Braz J Med Biol Res 48: 863-870.
31. Zhang Q, Lv H, Chen A, et al., 2012. Efficacy of infliximab in a rabbit model of osteoarthritis. Connect Tissue Res 53: 355-358.
32. Urech DM, Feige U, Ewert S, et al., 2010. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis 69: 443-449.
33. Maksymowych WP, Russell AS, Chiu P, et al., 2012. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther 14: R206.
34. Verbruggen G, Wittoek R, Vander Cruyssen B, et al., 2012. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71: 891-898.
35. Grunke M, Schulze-Koops H,. 2006. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 65: 555-556.